Investment Thesis
Kairos Pharma is a pre-revenue pharmaceutical company with significant cash burn (-$1.0M operating cash flow) and limited runway of approximately 3-4 quarters at current burn rate. With no revenue generation, negative net income of -$1.7M, and complete reliance on existing cash reserves, the company faces critical sustainability challenges without near-term commercialization or funding.
Strengths
- Strong liquidity position with 10.31x current ratio and quick ratio
- Conservative balance sheet with zero long-term debt and 0.00x debt-to-equity ratio
- Cash reserves of $3.7M providing near-term operational runway
Risks
- No revenue generation; company appears to be pre-commercialization pharmaceutical venture
- Severe cash burn rate of -$1.0M per quarter with limited runway remaining
- Negative profitability: -$1.7M net income with deteriorating EPS (-30.4% YoY), resulting in -31.1% ROE and -28.8% ROA
- Zero insider buying activity in past 90 days suggests lack of management confidence
- Extremely small asset base ($5.7M total assets) with minimal operational scale
Key Metrics to Watch
- Quarterly cash burn rate and runway remaining until capital requirements
- Revenue generation milestones or commercial product launch timeline
- Clinical trial progress updates and regulatory approval status for pipeline
- Capital raising activities and partnership announcements
Financial Metrics
Revenue
N/A
Net Income
-1.7M
EPS (Diluted)
$-0.08
Free Cash Flow
-1.0M
Total Assets
5.7M
Cash
3.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-31.1%
ROA
-28.8%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
10.31x
Quick Ratio
10.31x
Debt/Equity
0.00x
Debt/Assets
17.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:36:56.396142 |
Data as of: 2026-03-31 |
Powered by Claude AI